Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of HLA-Matched Non-Myeloablative Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation as Treatment for Patients With Metastatic Renal Cell Carcinoma. A Multi-Center Trial.

NCT00005851 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT00005851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of HLA-Matched Non-Myeloablative Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation as Treatment for Patients With Metastatic Renal Cell Carcinoma. A Multi-Center Trial.
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2000
Completion date
September 27, 2018
Enrollment
11 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent renal cell cancer, stage iv renal cell cancer